A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis

Recruiting

Phase 2

Phase 3

NipocalimabA Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis

Sponsor:

Janssen Research & Development, LLC

Code:

NCT05265273

Conditions

Myasthenia Gravis

Eligibility Criteria

Sex: All

Age: 2 - 17

Healthy Volunteers: Not accepted

Interventions

Nipocalimab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-04-17. This information was provided to ClinicalTrials.gov by Janssen Research & Development, LLC on 2025-04-10.